AngioDynamics, Inc. (ANGO) Given Average Rating of “Hold” by Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has been given an average recommendation of “Hold” by the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.00.

A number of brokerages have recently commented on ANGO. Canaccord Genuity restated a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a research note on Sunday, October 8th. Zacks Investment Research downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. TheStreet downgraded AngioDynamics from a “b-” rating to a “c” rating in a research report on Tuesday, January 2nd. Craig Hallum downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Finally, BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th.

Shares of AngioDynamics (NASDAQ ANGO) traded down $0.45 on Friday, hitting $17.25. The stock had a trading volume of 218,516 shares, compared to its average volume of 284,649. AngioDynamics has a 1 year low of $14.80 and a 1 year high of $18.85. The company has a quick ratio of 1.65, a current ratio of 2.56 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $650.39, a P/E ratio of -82.14, a price-to-earnings-growth ratio of 1.64 and a beta of 0.98.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The firm had revenue of $86.70 million for the quarter, compared to the consensus estimate of $88.15 million. During the same quarter in the prior year, the business earned $0.19 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. equities research analysts expect that AngioDynamics will post 0.72 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Teachers Advisors LLC boosted its position in AngioDynamics by 9.0% during the second quarter. Teachers Advisors LLC now owns 84,021 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 6,928 shares in the last quarter. QS Investors LLC boosted its position in AngioDynamics by 37.3% during the second quarter. QS Investors LLC now owns 42,351 shares of the medical instruments supplier’s stock worth $687,000 after purchasing an additional 11,504 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in AngioDynamics by 44.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 339,972 shares of the medical instruments supplier’s stock worth $5,511,000 after purchasing an additional 105,414 shares in the last quarter. Bessemer Group Inc. boosted its position in AngioDynamics by 13.9% during the third quarter. Bessemer Group Inc. now owns 63,200 shares of the medical instruments supplier’s stock worth $1,080,000 after purchasing an additional 7,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in AngioDynamics by 32.1% during the second quarter. The Manufacturers Life Insurance Company now owns 29,321 shares of the medical instruments supplier’s stock worth $475,000 after purchasing an additional 7,130 shares in the last quarter. Institutional investors own 94.83% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “AngioDynamics, Inc. (ANGO) Given Average Rating of “Hold” by Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/03/angiodynamics-inc-ango-given-average-rating-of-hold-by-analysts.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply